The city of Baltimore, Maryland, currently has 8 active clinical trials seeking participants for Parkinson's Disease research studies.
A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
NCT06680830
Recruiting
The goal of this Phase 2 clinical trial is to investigate the efficacy and safety of NEU-411 in men and women aged 40-80 years with early Parkinson's Disease (PD) who have predicted elevations in the activity of the "leucine-rich repeat kinase 2" ("LRRK2" for short) pathway based on their genetic profile. A DNA test will be used to identify the "LRRK2-driven" population with predicted elevation in the LRRK2 pathway. Participants will: • Take NEU-411 or placebo every day for 52 weeks
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
08/18/2025
Locations: University of Maryland, Baltimore, Maryland
Conditions: Parkinson Disease, Parkinson, Idiopathic Parkinson Disease, Early Parkinson Disease (Early PD), Parkinson Disease, Idiopathic
Register for Updates
PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort
NCT04477785
Recruiting
The Parkinson Progression Marker Initiative (PPMI) is a longitudinal, observational, multi-center natural history study to assess progression of clinical features, digital outcomes, and imaging, biologic and genetic markers of Parkinson's disease (PD) progression in study participants with manifest PD, prodromal PD, and healthy controls. The overall goal of PPMI is to identify markers of disease progression for use in clinical trials of therapies to reduce progression of PD disability.
Gender:
ALL
Ages:
30 years and above
Trial Updated:
07/15/2025
Locations: Johns Hopkins University, Baltimore, Maryland
Conditions: Parkinson Disease
Register for Updates
First-in-Human Single and Multiple Dose of HL-400
NCT06997484
Recruiting
This is a randomized, double-blind, placebo-controlled, dose-escalation study in healthy subjects to evaluate the safety, tolerability, pharmacokinetics of HL-400 (a NLRP3 inhibitor) following oral single and multiple ascending dose administration.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/21/2025
Locations: Pharmaron CPC, Inc., Baltimore, Maryland
Conditions: Parkinson Disease
Register for Updates
Parkinson's Foundation PD GENEration Genetic Registry
NCT04994015
Recruiting
Development of a central repository for PD-related genomic data for future research.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2025
Locations: Johns Hopkins, Baltimore, Maryland
Conditions: Parkinson's Disease
Register for Updates
Effects of RAS on Gait in PD Patients With DBS
NCT05763732
Recruiting
Participants will be asked to walk along with the metronome beats (RAS) during the participants' stimulation state (ON or OFF) for four minutes for each state. The researcher will collect the gait parameters (cadence, velocity, and stride length) of patients before, during, and after RAS in both DBS ON and OFF states. Using MDS-UPDRS, participants' gait patterns will be collected before and after RAS while both DBS is ON and OFF. Electrophysiological activity (local field potentials, LFPs) wil... Read More
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
04/08/2025
Locations: Johns Hopkins School of Medicine, Baltimore, Maryland
Conditions: Parkinson Disease
Register for Updates
Black and African Americans Connections to Parkinson's Disease (BLAAC PD)
NCT06719583
Recruiting
BLAAC PD is a research study to understand what Parkinson's disease looks like for Black and African American communities. BLAAC PD is happening at research centers around the United States. The study is part of the Global Parkinson's Genetics Program (GP2). GP2 is a research project working to transform understanding of the genetics of Parkinson's disease and make that knowledge globally relevant.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/02/2024
Locations: University of Maryland, Baltimore, Maryland
Conditions: Parkinson Disease
Register for Updates
Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis
NCT05824728
Recruiting
This clinical trial will test whether AGB101 (low-dose levetiracetam, 220 mg, extended release tablet) can improve symptoms of psychosis in Parkinson's disease. Participants will be asked to complete up to 5 in-person study visits over approximately 20 weeks. Participants will receive both AGB101 and a placebo to take once a day for 6 weeks, with a 4-week washout in between. Participation will also involve physical/neurological exams, questionnaires, paper and pencil tests, providing blood and u... Read More
Gender:
ALL
Ages:
Between 40 years and 85 years
Trial Updated:
10/10/2024
Locations: Johns Hopkins, Baltimore, Maryland
Conditions: Parkinson Disease Psychosis
Register for Updates
A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Pallidotomy for the Treatment of Advanced, Idiopathic Parkinson's Disease With Medication-refractory Moderate to Severe Motor Complications
NCT05539196
Recruiting
This registry is a prospective, multicenter, international, single arm, observational post-approval registry with follow-up at 3, 6, and 12 months, and annually for 5 years. The proposed registry will enroll 60 subjects and will be conducted at approximately 10 centers worldwide.
Gender:
ALL
Ages:
Between 30 years and 99 years
Trial Updated:
05/30/2024
Locations: University of Maryland, Baltimore, Baltimore, Maryland
Conditions: Movement Disorders, Neurology, Parkinsons Disease
Register for Updates